Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

Inclusion Criteria:

• The informed consent form signed by the patient's parent/adoptive parent toparticipate in the clinical study.

• Male and female patients aged 3-6.

• Patients with moderate course of influenza or other acute respiratory viralinfections.

• Patients with clinically diagnosed influenza or other ARVI based on the bodytemperature > 37,5 ° C, not less than 1 of the following other symptoms ofintoxication and not less than 1 of the following of catarrhal symptoms:

• Intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs;

• Catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion.

• Established diagnosis J06.9, J10, J11, in accordance with ICD-10.

• Uncomplicated course of influenza and other ARVI.

• Interval between onset of symptoms and enrollment to the study of not more than 36hours.

Exclusion Criteria:

• Complicated course of influenza and other acute respiratory viral infections.

• Treatment with antiviral drugs (antivirals, interferons and interferon inducers),drugs with immunomodulatory effects or antibiotics with systemic and local actionwithin 14 days prior to the screening visit.

• Severe influenza or other ARVI with symptoms of cardiovascular disease, and othersymptoms of infectious-toxic shock, and meningoencephalitic syndromes.

• Signs of primary viral pneumonia development (presence of two or more of the followingsymptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullnessof percussion sound at symmetrical assessment of the upper and lower parts of thelungs.

• Infectious diseases within the last week prior to enrollment.

• "RRI children" (incidence of ARVI within the last 12 months is 6 times or more).

• Asthma history.

• History of increased seizure activity.

• Severe decompensated or unstable medical or psychiatric conditions (any diseases orconditions that threaten the life of the patient or worsen the patient's prognosis andalso make it impossible to conduct a clinical study in the patient).

• Cancer, HIV infection, tuberculosis, including those in history.

• Hypersensitivity to imidazolyl ethanamide pentandioic acid and/or excipients ofIngavirin product.

• Diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption,deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucosemalabsorption, deficiency of glucose-6-phosphate dehydrogenase.

• Participation of the patient in any other clinical trial within the last 90 days priorto enrollment.